Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.69 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | PAICS | P22234 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1317664 | 0.95 | HDAC1 (0.64) | HDAC1CCNCCDK8PAICSHDAC3 | |
| SCHEMBL12117894 | 0.90 | HDAC1 (0.59) | HDAC1CCNCCDK8PAICSBACE1 | |
| SCHEMBL12117920 | 0.90 | HDAC1 (0.55) | HDAC1HDAC3BACE1ACLY | |
| Hydrochloric Acid SCHEMBL1315802 | 0.89 | HDAC1 (0.54) | HDAC1HDAC3BACE1ACLY | |
| SCHEMBL2569866 | 0.88 | HDAC1 (0.69) | HDAC1BACE1ACLY | |
| SCHEMBL13206290 | 0.88 | HDAC1 (0.56) | HDAC1HDAC3BACE1ACLY | |
| SCHEMBL12117908 | 0.87 | HDAC1 (0.57) | HDAC1HDAC3BACE1ACLY | |
| SCHEMBL12117913 | 0.87 | HDAC1 (0.59) | HDAC1BACE1ACLY | |
| SCHEMBL1316090 | 0.86 | HDAC1 (0.54) | HDAC1CCNCCDK8BACE1ACLY | |
| SCHEMBL12117911 | 0.85 | HDAC1 (0.58) | HDAC1BACE1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-8492582-B2 | N-acyl anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-07-23 | — | — | US | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-11-10 | — | — | US | disclosed |
| WO-2010087430-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | 富山化学工業株式会社 (JP) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275797-A1 | N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | COL14A1, COL2A1, COL1A1 | HDAC1 73/4885CCNC 3376/4885CDK8 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.